ESR1 and breast carcinoma: SERMs are structurally diverse compounds that bind the ER and elicit ligand- and tissue-specific effects [6,7], such as inhibiting the proliferative effects of estrogen in ER-positive breast cancers, while maintaining partial agonistic activity in other tissues [8].